Glaukos Market Capitalization from 2010 to 2024
| GKOS Stock | USD 142.94 1.06 0.74% |
Check Glaukos Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Glaukos Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 39.9 M, Selling General Administrative of 120.2 M or Selling And Marketing Expenses of 1.7 M, as well as many indicators such as Price To Sales Ratio of 14.85, Dividend Yield of 0.0 or PTB Ratio of 8.75. Glaukos financial statements analysis is a perfect complement when working with Glaukos Corp Valuation or Volatility modules.
Glaukos | Market Capitalization |
Latest Glaukos Corp's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Glaukos Corp over the last few years. It is Glaukos Corp's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Glaukos Corp's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 7.94 B | 10 Years Trend |
|
Market Cap |
| Timeline |
Glaukos Market Capitalization Regression Statistics
| Arithmetic Mean | 2,592,402,283 | |
| Geometric Mean | 2,470,075,433 | |
| Coefficient Of Variation | 33.70 | |
| Mean Deviation | 787,025,402 | |
| Median | 1,966,101,771 | |
| Standard Deviation | 873,741,822 | |
| Sample Variance | 763424.8T | |
| Range | 1.9B | |
| R-Value | 0.69 | |
| Mean Square Error | 427760.9T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 135,317,810 | |
| Total Sum of Squares | 10687946.8T |
Glaukos Market Capitalization History
About Glaukos Corp Financial Statements
Glaukos Corp shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Glaukos Corp investors may analyze each financial statement separately, they are all interrelated. The changes in Glaukos Corp's assets and liabilities, for example, are also reflected in the revenues and expenses on on Glaukos Corp's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. Glaukos Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 727 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.